Cash Flow Statement (Annual)

ORGS / Orgenesis, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2010 2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Profit Loss -36 -72 - - - - - -
  Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Share Based Compensation - 0 2,977 2,796 1,200 803 2,869 3,364
    Gain Loss On Investments - - - - - 0 -123 -1,214
    Gains Losses On Extinguishment Of Debt - - - - - 0 -229 0
    Depreciation And Amortization - - - - - 1,991 2,923 2,598
    Derivative Gain Loss On Derivative Net - - 0 133 180 1,375 -187 826
    Change In Fair Value Of Convertible Bonds - - - - 0 1,221 84 192
    Interest Expense Short Term Borrowings - - 0 173 1,086 502 283 1,110
  Increase Decrease In Operating Capital
    Increase Decrease In Accounts Receivable - - - - 0 731 54 -33
    Increase Decrease In Inventories - - - - 0 87 101 265
    Increase Decrease In Due To Related Parties Current 0 35 7 0 - - 0 -583
    Increase Decrease In Other Current Assets - - - - 0 22 17 3
    Increase Decrease In Prepaid Expense 0 -1 27 9 74 1,083 -136 107
    Increase Decrease In Accounts Payable 5 38 91 3 1,016 1,497 1,079 -933
    Increase Decrease In Accrued Liabilities - 0 68 313 -11 538 399 92
    Increase Decrease In Due To Other Related Parties - 0 76 79 471 353 352 1,142
    Increase Decrease In Deferred Revenue - - - - 0 1,039 53 1,044
    Increase Decrease Increase Decrease In Advance Payment On Account Of Grant - - - 0 -726 451 499 2,156
    Increase Decrease In Accrued Income Taxes Payable - - - - 0 -900 -1,546 -1,310
  Net Cash Provided By Used In Operating Activities -15 -0 -1,052 -1,989 -1,429 -2,706 -3,783 -3,833
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Property Plant And Equipment - 0 10 8 5 982 1,425 975
  Proceeds From Sale Of Property Plant And Equipment - - - - - - - -
  Payments For Proceeds From Investments - - - - - 0 111 2,429
  Net Cash Provided By Used In Investing Activities 0 0 -21 -10 3 -932 -1,536 -3,404
Net Cash Provided By Used In Financing Activities
  Proceeds From Repayments Of Lines Of Credit - - - - - - 21 -21
  Proceeds From Issuance Of Common Stock 0 0 1,072 1,800 922 4,203 1,488 5,297
  Proceeds From Payments For Other Financing Activities - - 0 250 - - 1,121 0
  Proceeds From Repayments Of Redeemable Non Controlling Interest - - - - - - 0 2,349
  Proceeds From Notes Payable - - - - 0 3,946 1,121 -
  Proceeds From Convertible Debt - - - 250 1,750 950 1,599 5,899
  Repayments Of Convertible Debt - - - - - - 0 4,051
  Repayments Of Long Term Debt - - - - 0 2,419 2,106 1,108
  Net Cash Provided By Used In Financing Activities 0 0 1,072 2,050 2,737 6,666 2,123 8,365
Cash And Cash Equivalents Period Increase Decrease -15 -0 -1 50 1,310 3,028 -3,196 1,128
Effect Of Exchange Rate On Cash And Cash Equivalents - - - 0 -47 -174 -81 1,497
Cash And Cash Equivalents At Carrying Value - 1 0 51 1,314 4,168 891 3,519
Supplemental Cash Flow Information
  Conversion Of Loans To Shares Of Common Stock And Warrants - - - - 631 0 1,028 1,277
  Reclassification Of Redeemable Non Controlling Interest To Equity - - - - - - 21,458 0
  Leasing Of Fixed Assets - - - - - - - -
  Stock Issued1 - - - 0 37 0 - -
  Warrants To Be Issued To Credit Providers - - - - 0 208 0 -
  Supplemental Information On Interest Paid In Cash - - - - 0 125 106 903

Peers - Pharmaceutical Preparations (2834)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 68619K105